Tackle Lung Cancer by Means of Novel Immunotherapeutic Strategies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 1554
Special Issue Editors
Interests: inflammasome; immunology; lung cancer
Special Issue Information
Dear Colleagues,
Lung cancer is the most common solid tumor and the leading cause of cancer-related death worldwide. The actual treatment is based on immunecheckpoint inhibitors (ICIs) and conventional chemotherapy. Nevertheless, both non-responsiveness and long-term resistance have been registered.
Monoclonal antibodies against PD-1 and PD-L1, immunecheckpoints, are actually used in clinical practice, but other antibodies that can circumevent both innate and acquired resistance are on their way of being pre-clinically and clinically studied. Other pharmacological tools to tackle cancer are conventional chemotherapeutics and tyrosine kinase inhibitors. The above therapeutic tools have the goal to both modulate the immune system to edit cancer but also to induce cancer cell death in an immunogenic manner. In this scenario, it is noteworthy to highlight that some “old” drugs are being repurposed in that it was highlighted that they can boost ICIs and/or tyrosine kinase inhibitors to exploit higher efficacy. Nevertheless, tumor cells can develop and facilitate the tolerogenic nature of the tumor microenvironment, resulting in an unexpected tumor progression. Therefore, the immune escape mechanism(s) exploited by growing lung cancer represents a fine interplay between all the actors in the TME. A better understanding of the molecular biology of lung cancer and the cellular/molecular mechanisms involved in the crosstalk between lung cancer cells and immune cells in the TME as well as old drug repurposing could identify novel therapeutic weapons in the old war against lung cancer.
Dr. Chiara Colarusso
Prof. Dr. Rosalinda Sorrentino
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
